EP1684077A1 - Verfahren zur Identifizierung von Modulatoren wechselwirkender Proteine - Google Patents

Verfahren zur Identifizierung von Modulatoren wechselwirkender Proteine Download PDF

Info

Publication number
EP1684077A1
EP1684077A1 EP06000197A EP06000197A EP1684077A1 EP 1684077 A1 EP1684077 A1 EP 1684077A1 EP 06000197 A EP06000197 A EP 06000197A EP 06000197 A EP06000197 A EP 06000197A EP 1684077 A1 EP1684077 A1 EP 1684077A1
Authority
EP
European Patent Office
Prior art keywords
protein
proteins
binding
kda
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP06000197A
Other languages
English (en)
French (fr)
Inventor
Elias Georges
Original Assignee
McGill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McGill University filed Critical McGill University
Priority claimed from EP00929188A external-priority patent/EP1179186B1/de
Publication of EP1684077A1 publication Critical patent/EP1684077A1/de
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding

Definitions

  • the present invention relates to proteonomics. More specifically, the invention relates to protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction.
  • Protein-protein interactions are critical events in biological processes. Protein-protein interactions govern biological processes that handle cellular information flow and control cellular decisions (e.g., signal transduction, cell cycle regulation and assembly of cellular structures).
  • the entire network of interactions between cellular proteins is a biological chart of functional events that regulate the internal working of living organisms and their responses to external signals.
  • a necessary step for the completion of this biological interaction chart is the knowledge of all the gene sequences in a given living organism.
  • the entire DNA sequence of the homo sapiens genome will be completed at the latest by the year 2003 (29). Unfortunately, the sequence of a gene does not reveal its biological function nor its position in the biological chart. Given the expected number of proteins in the human genome (80,000 to 120,000), the mapping of the biological chart of protein-protein interactions will be an enormous but a rewarding task.
  • transcription of reporter genes depends on an interaction between a DNA-bound "bait" protein and an activation-domain containing "prey” protein.
  • the two hybrid systems unfortunately may suffer from a number of disadvantages. For example, the interaction of proteins is monitored in the nuclear milieu rather than the cytoplasm where most proteins are found and it does not allow the simultaneous identification of the precise amino acid sequences between two interacting proteins and cannot be easily applied to different cell types or tissues whereby different interacting proteins may be expressed.
  • the present invention seeks to meet these and other needs.
  • the present invention seeks to overcome the drawbacks of the prior art. More specifically, the invention concerns an approach to identify protein-protein interaction domains which differ from the priorart. Moreover, one approach of the present invention is based on an understanding of the principle that govern protein-protein interactions. Such understanding therefore, allows the use of several methods. Such a method is exemplified in detail below to identify: i) at least one of the exact amino acid sequences between interacting proteins; ii) a number of, possibly all interacting proteins in different cells or tissues; and iii) the specific domains (or sequences) between two interacting proteins as targets for isolation of lead drugs. Preferably, the method and assay of the present invention enables a determination of i), ii) and iii). Moreover, unlike the approaches of the prior art, the method described herein, allows for the identification of interacting proteins and the precise amino acid sequences of interactions in several days as opposed to several months.
  • the present invention further relates to a novel approach in drug discovery.
  • Amajor obstacle in drug development for the treatment of diseases has been the identification of target proteins and their functional sites.
  • R&D research and development
  • drugs identified by current approaches often target the active sites in proteins. Such drugs thus often lead to major side-effects). Therefore, it is not surprising that many R&D projects never lead to the development of specific drugs even after three to five years of intensive research efforts.
  • the methods and assays to identify protein-protein interactions of the present invention may address three important steps in the development of drugs:
  • P-glycoprotein has been shown to cause multidrug resistance in tumor cell lines selected with lipophilic anticancer drugs.
  • Analysis of P-gp amino acid sequence has lead to a proposed model of a duplicated molecule with two hydrophobic and hydrophilic domains linked by a highly charged region of circa 90 amino acids, the linker domain.
  • similarly charged domains are found in other members of the P-gp superfamily, the function(s) of this domain are not known.
  • this domain binds toother cellular proteins.
  • a method of identifying a high-affinity interacting domain ina chosen protein, domain thereof or part thereof and the amino acid sequence thereof comprising: a) providing a set of overlapping peptides spanning a complete sequence of the chosen protein, domain thereof or part thereof, covalently bound to a support; b) providing a mixture of proteins and/or a mixture of peptides; incubating the set of overlapping peptides of a), with the mixture of b), under conditions enabling the binding between a high-affinity interacting domain in a peptide of the set and one or more proteh or peptide of b) to occur; d) washing of any protein-protein interaction which is not a high-affinity interaction of c); and e) identifying which peptide of a) interacts with high-affinity to a protein or peptide of b); thereby identifying the peptide of e) and the sequence thereof as a high-affinity
  • a method of identifying an agent which modulates an interaction between high-affinity interacting domains between a set of overlapping peptides spanning a complete sequence of a chosen protein, domain thereof or part thereof, covalently bound to a support and a mixture of proteins and/or a mixture of peptides comprising: a) incubating the set of overlapping peptides, with the mixture in a presence of at least one agent, under conditions enabling the binding between a high-affinity interacting domain ina peptide of the set and one or more protein or peptide of the mixture to occur; b) washing of any protein-protein interaction which is not a high-affinity interaction of b); and c) identifying which peptide ofa) interacts with high-affinity to a protein or peptide of the mixture in a presence of the agent as compared to in an absence thereof; thereby identifying the agent as a modulator of thehigh-affinity interaction when the interaction in the
  • agents identified as modulators of the high-affinity protein interactions of the present invention there is provided agents identified as modulators of the high-affinity protein interactions of the present invention.
  • overlapping peptides spanning a peptide sequence refers to peptides of a chosen size, based on the sequence of the protein (or part thereof).
  • these peptides are synthetic peptides.
  • the size of the overlapping peptides has a significant impact on the workings of the present invention.
  • peptides of four contiguous amino acids appear to significantly increase the low affinity binding of proteins thereto.
  • larger peptides such as 20 amino acids or higher, would be expected to increase the proportion of repulsive amino acids to high affinity amino acids, thereby masking or totally inhibiting the binding of specific proteins to the peptides.
  • the preferred size for the overlapping peptides of the present invention is between 5 and 15 amino acids, more preferably between 5 and 12, and especially preferably between 5 and 10 amino acids.
  • support in the context of a support to which the overlapping peptides of the present invention are covalently bound, can be chosen from a multitude of supports found in the art. Such supports include CHIPS, plates (e.g. 96-well plates), glass beads and the like).
  • CHIP technology is well-known in the art. Reference relating thereto include Debouck et al., Nat Genet. 1999 Jan;21(1 Suppl):48-50, Review; Brownet al., Nat Genet. 1999 Jan;21(1 Suppl):33-7, Review; Cheung et al., Nat Genet. 1999 Jan;21(1 Suppl):15-9, Review; Duggan et al., Nat Genet.
  • Protein sequences are presented herein using the one letter or three letter amino acid symbols as commonly used in the art and in accordance with the recommendations of the IUPAC-IUB Biochemical Nomenclature Commission.
  • rDNA recombinant DNA
  • nucleic acid molecule refers to a polymer of nucleotides. Non-limiting examples thereof include DNA (e.g. genomic DNA, cDNA) and RNA molecules (e.g. mRNA). The nucleic acid molecule can be obtained by cloning techniques or synthesized. DNA can be double-stranded or single-stranded (coding strand or non-coding strand [antisense]).
  • recombinant DNA refers to a DNA molecule resulting from the joining of DNA segments. This is often eferred to as genetic engineering.
  • DNA segment is used herein, to refer to a DNA molecule comprising a linear stretch or sequence of nucleotides. This sequence when read in accordance with the genetic code, can encode a linear stretch or sequence of amino acids which can be referred to as a polypeptide, protein, protein fragment and the like.
  • amplification pair refers herein to a pair of oligonucleotides (oligos) of the present invention, which are selected to be used together in amplifying a selected nucleic acid sequence by one of a number of types of amplification processes, preferably a polymerase chain reaction.
  • amplification processes include ligase chain reaction, strand displacement amplification, or nucleic acid sequence-based amplification, as explained in greater detail below.
  • the oligos are designed to bind to a complementary sequence under selected conditions.
  • the nucleic acid e.g. DNA or RNA
  • the nucleic acid may be obtained according to well known methods.
  • physiologically relevant is meant to describe interactions which can take effect to modulate an activity or level of one or more proteins in their natural setting.
  • DNA molecule or sequence (as well as sometimes the term “oligonucleotide”) refers to a molecule comprised of the deoxyribonucleotides adenine (A), guanine (G), thymine (T) and/or cybsine (C), in a double-stranded form, and comprises or includes a "regulatory element” according to the present invention, as the term is defined herein.
  • oligonucleotide” or “DNA” can be found in linear DNA molecules or fragments, viruses, plasmids, vectors, chromosomes or synthetically derived DNA. As used herein, particular double-stranded DNA sequences may be described according to the normal convention of giving only the sequence in the 5' to 3' direction.
  • Nucleic acid hybridization refers generally to the hybridization of two single-stranded nucleic acid molecules having complementary base sequences, which under appropriate conditions will form a thermodynamically favored double-stranded structure. Examples of hybridization conditions can be found in the two laboratory manuals referred above (Sambrook et al., 1989, supra and Ausubel et al., 1989, supra) and are commonly known in the art.
  • a nitrocellulose filter can be incubated overnight at 65°C with a labeled probe in a solution containing 50% formamide, high salt (5 x SSC or 5 x SSPE), 5 x Denhardt's solution, 1% SDS, and 100 ⁇ g/ml denatured carrier DNA (e.g. salmon sperm DNA).
  • the non-specifically binding probe can then be washed off the filter by several washes in 0.2 x SSC/0.1% SDS at a temperature which is selected in view of the desired stringency: room temperature (low stringency), 42°C (moderate stringency) or 65°C (high stringency).
  • the selected temperature is based on the melting temperature (Tm) of the DNA hybrid.
  • Tm melting temperature
  • RNA-DNA hybrids can also be formed and detected.
  • the conditions of hybridization and washing can be adapted according to well known methods by the person of ordinary skill. Stringent conditions will be preferably used (Sambrook et al., 1989, supra).
  • Probes for nucleic acids can be utilized with naturally occurring sugar-phosphate backbones as well as modified backbones including phosphorothioates, dithionates, alkyl phosphonates and ⁇ -nucleotides and the like. Modified sugar-phosphate backbones are generally taught by Miller, 1988, Ann. Reports Med. Chem. 23: 295 and Moran et al., 1987, Nucleic Acids Res., 14:5019. Probes of the invention can be constructed of either ribonucleic acid (RNA) or deoxyribonucleic acid (DNA), and preferably of DNA.
  • RNA ribonucleic acid
  • DNA deoxyribonucleic acid
  • he detection of the interaction between proteins and/or peptides be dependent on a label.
  • labels provide sensitivity and often enable automation.
  • automation is performed using CHIP technology.
  • the overlapping peptides, spanning a chosen sequence of a protein are bound to a CHIP which can then be used to automate a testing for interaction with proteins or peptides.
  • the present invention is not strictly dependent on a design and synthesis of the overlapping set of peptides spanning a chosen protein sequence. Indeed, banks of peptides are available, from which this set of overlapping peptides could be constructed.
  • Protein labelling is well-known in the art.
  • a non-limiting example of labels includes 3 H, 14 C, 32 P, and 35 S.
  • Non-limiting examples of detectable markers include ligands, fluorophores, chemiluminescent agents, enzymes, and antibodies. It will become evident to the person of ordinary skill that the choice of a particular label dictates the manner in which it is bound to the protein.
  • the identification of the interaction is not specifically dependent on labelling of the proteins, since for example, this interaction could be assessed using proteomic approaches (such as 2D gels and mass spectometry) or using a library of antibodies.
  • radioactive nucleotides can be incorporated into peptides or proteins of the invention by several well-known methods.
  • a non-limiting example thereof includes in vitro or in vivo labelling of proteins using 35 SMet.
  • vector is commonly known in the art and defines a plasmid DNA, phage DNA, viral DNA and the like, which can serve as a DNA vehicle into which DNA of the present invention can be cloned. Numerous types of vectors exist and are well known in the art.
  • expression defines the process by which a gene is transcribed into mRNA (transcription), the mRNA is then being translated (translation) into one polypeptide (or protein) or more.
  • expression vector defines a vector or vehicle as described above but designed to enable the expression of an inserted sequence following transformation into a host.
  • the cloned gene (inserted sequence) is usually placed under the control of control element sequences such as promoter sequences.
  • control element sequences such as promoter sequences.
  • the placing of a cloned gene under such control sequences is often referred to as being operably linked to control elements or sequences.
  • Operably linked sequences may also include two segments that are transcribed onto the same RNA transcript.
  • two sequences such as a promoter and a "reporter sequence” are operably linked if transcription commencing in the promoter will produce an RNA transcript of the reporter sequence.
  • a promoter and a reporter sequence are operably linked if transcription commencing in the promoter will produce an RNA transcript of the reporter sequence.
  • Expression control sequences will vary depending on whether the vector is designed to express the operably linked gene in a prokaryotic or eukaryotic host or both (shuttle vectors) and can additionally contain transcriptional elements such as enhancer elements, termination sequences, tissue-specificity elements, and/or translational initiation and termination sites.
  • Prokaryotic expressions are useful for the preparation of large quantities of the protein encoded by the DNA sequence of hterest.
  • This protein can be purified according to standard protocols that take advantage of the intrinsic properties thereof, such as size and charge (e.g. SDS gel electrophoresis, gel filtration, centrifugation, ion exchange chromatography).
  • the protein of interest can be purified via affinity chromatography using polyclonal or monoclonal antibodies. The purified protein can be used for therapeutic applications.
  • the DNA construct can be a vector comprising a promoter that is operably linked to an oligonucleotide sequence of the present invention, which is in turn, operably linked to a heterologous gene, such as the gene for the luciferase reporter molecule.
  • Promoter refers to a DNA regulatory region capable of binding directly or indirectly to RNA polymerase in a cell and intiating transcription of a downstream (3' direction) coding sequence.
  • the promoter is bound at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background.
  • RNA polymerase a transcription initiation site (conveniently defined by mapping with S1 nuclease), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase.
  • Eukaryotic promoters will often, but not always, contain "TATA” boses and “CCAT” boxes.
  • Prokaryotic promoters contain Shine-Dalgarno sequences in addition to the -10 and -35 consensus sequences.
  • the designation "functional derivative” denotes, in the context of a functional derivative of a sequence whether an nucleic acid or amino acid sequence, a molecule that retains a biological activity (either function or structural) that is substantially similar to that of the original sequence.
  • This functional derivative or equivalent may be a natural derivative or may be prepared synthetically.
  • Such derivatives include amino acid sequences having substitutions, deletions, or additions of one or more amino acids, provided that the biological activity of the protein is conserved.
  • derivatives of nucleic acid sequences which can have substitutions, deletions, or additions of one or more nucleotides, provided that the biological activity of the sequence is generally maintained.
  • the substituting amino acid When relating to a protein sequence, the substituting amino acid as chemico-physical properties which are similar to that of the substituted amino acid.
  • the similar chemico-physical properties include, similarities in charge, bulkiness, hydrophobicity, hydrophylicity and the like.
  • the term “functional derivatives” is intended to include “fragments”, “segments”, “variants”, “analogs” or “chemical derivatives” of the subject matter of the present invention.
  • a conservative mutation or substitution of an amino acid refers to mutation or substitution which maintains 1) the structure of the backbone of the polypeptide (e.g. a beta sheet or alpha-helical structure); 2) the charge or hydrophobicity of the amino acid; or 3) the bulkiness of the side chain. More specifically, the well-known terminologies "hydrophilic residues" relate to serine or threonine. "Hydrophobic residues” refer to leucine, isoleucine, phenylalanine, valine or alanine. "Positively charged residues” relate to lysine, arginine or hystidine. Negatively charged residues” refer to aspartic acid or glutamic acid. Residues having "bulky side chains” refer to phenylalanine, tryptophan or tyrosine.
  • Peptides, protein fragments, and the like in accordance with the present invention can be modified in accordance with well-known methods dependently or independently of the sequence thereof.
  • peptides can be derived from the wild-type sequence exemplified herein in the figures using conservative amino acid substitutions at 1, 2, 3 or more positions.
  • conservative amino acid substitutions is well-known in the art which relates to substitution of a particular amino acid by one having a similar characteristic (e.g. aspartic acid for glutamic acid, or isoleucine for leucine).
  • non-conservative amino acid substitutions can also be carried out, as well as other types of modifications such as deletions or insertions, provided that these modifications modify the peptide, in a suitable way (e.g. without affecting the biological activity of the peptide ifthis is what is intended by the modification).
  • modifications of the peptides can also be effected without affecting the primary sequence thereof using enzymatic or chemical treatment as well-known in the art.
  • variant refers herein to a protein or nucleic acid molecule which is substantially similar in structure and biological activity to the protein or nucleic acid of the present invention.
  • a variant according to the present invention can be identified with a method of the present invention. It can also be designed to formally test for the conservation of particular amino acids (e.g. by synthesizing a variant or mutant peptide). These variants can also be tested as part of the full length sequence of the protein in order to validate the interaction.
  • chemical derivatives is meant to cover additional chemical moieties not normally part of the subject matter of the invention. Such moieties could affect the physico-chemical characteristic of the derivative (e.g. solubility, absorption, half life and the like, decrease of toxicity).
  • allele defines an altemative form of a gene which occupies a given locus on a chromosome.
  • a “mutation” is a detectable change in the genetic material which can be transmitted to a daughter cell.
  • a mutation can be, for example, a detectable change in one or more deoxyribonucleotide.
  • nucleotides can be added, deleted, substituted for, inverted, or transposed to a new position.
  • Spontaneous mutations and experimentally induced mutations exist.
  • the result of a mutations of nucleic acid molecule is a mutant nucleic acid molecule.
  • a mutant polypeptide can be encoded from this mutant nucleic acid molecule.
  • purified refers to a molecule having been separated from a cellular component.
  • a purified protein has been purified to a level not found in nature.
  • a “substantially pure” molecule is a molecule that is lacking in most other cellular components.
  • molecule As used herein, the terms “molecule”, “compound” or “ligand” are used interchangeably and broadly to refer to natural, synthetic or semisynthetic molecules or compounds.
  • the term “molecule” therefore denotes for example chemicals, macromolecules, cell or tissue extracts (from plants or animals) and the like.
  • Non limiting examples of molecules include nucleic acid molecules, peptides, antibodies, carbohydrates and pharmaceutical agents.
  • the agents can be selected and screened by a variety of means including random screening, rational selection and by rational design using for example protein or ligand modelling methods such as computer modelling, combinatorial library screening and the like.
  • the terms “rationally selected” or “rationally designed” are meant to define compounds which have been chosen based on the configuration of the interaction domains of the present invention.
  • molecules having non-natural occurring modifications are also within the scope of the term "molecule".
  • peptidomimetics well known in the pharmaceutical industry and generally referred to as peptide analogs can be generated by modelling as mentioned above.
  • polypeptides of the present invention are modified to enhance their stability. Itshould be understood that in most cases this modification should not alter the biological activity of the interaction domain.
  • the molecules identified in accordance with the teachings of the present invention have a therapeutic value in diseases or conditions in which the physiology or homeostasis of the cell and/or tissue is compromised by a high-affinity protein interaction identified in accordance with the present invention.
  • the molecules identified in accordance with the teachings of the present invention find utility in the development of more efficient agents which can modulate such interactions.
  • Libraries of compounds are well-known in the art. Libraries of peptides are also available. Such libraries can be used to build an overlapping set of peptide sequences spanning a chosen domain, protein or part thereof.
  • indicator cells refers to cells that express, in one particular embodiment, two interacting peptide domains of the present invention, and wherein an interaction between these proteins or interacting domains thereof is coupled to an identifiable or selectable phenotype or characteristic such that it provides an assessment or validation of the interaction between same.
  • Such indicator cells can also be used in the screening assays of the present invention.
  • the indicator cells have been engineered so as to express a chosen derivative, fragment, homolog, or mutant of these interacting domains.
  • the cells can be yeast cells or higher eukaryotic cells such as mammalian cells (WO 96/41169).
  • the indicator cell is a yeast cell harboring vectors enabling the use of the two hybrid system technology, as well known in the art (Ausubel et al., 1994, supra) and can be used to test a compound or a library thereof.
  • a reporter gene encoding a selectable marker or an assayable protein can be operably linked to a control element such that expression of the selectable marker or assayable protein is dependent on the interaction of the Protein A and Protein B interacting domains.
  • the reporter gene is luciferase or ⁇ -Gal.
  • At least one of the two interacting proteins or domains of the present invention may be provided as a fusion protein.
  • the design of constructs therefor and the expression and production of fusion proteins are well known in the art (Sambrook et al., 1989, supra ; and Ausubel et al., 1994, supra).
  • both interaction domains are part of fusion proteins.
  • a non-limiting example of such fusion proteins includes a LexA-Protein A fusion (DNA-binding domain-Protein A; bait) and a B42-Protein B fusion (transactivator domain-Protein B; prey).
  • the LexA-Protein A and B42-Protein B fusion proteins are expressed in a yeast cell also harboring a reporter gene operably linked to a LexA operator and/or LexA responsive element.
  • a reporter gene operably linked to a LexA operator and/or LexA responsive element.
  • the fusion proteins need not contain the full-length interacting proteins. Indeed, fragments of these polypeptides, provided that they comprise the interacting domains, can be used in accordance with the present invention, as evidenced with the peptide spanning method of the present invention.
  • Non-limiting examples of such fusion proteins include a hemaglutinin fusions, Gluthione-S-transferase (GST) fusions and Maltose binding protein (MBP) fusions.
  • GST Gluthione-S-transferase
  • MBP Maltose binding protein
  • protease cleavage sites between two heterologously fused polypeptides are well known in the art.
  • the interaction domains of the present invention it might also be beneficial to fuse the interaction domains of the present invention to signal peptide sequences enabling a secretion of the fusion protein from the host cell.
  • Signal peptides from diverse organisms are well known in the art. Bacterial OmpA and yeast Suc2 ae two non limiting examples of proteins containing signal sequences.
  • Such fusion protein find utility in the assays of the present invention as well as for purification purposes, detection purposes and the like.
  • sequences and polypeptides useful to practice the invention include without being limited thereto mutants, homologs, subtypes, alleles and the like. It shall be understood that generally, the sequences of the present invention should encode a functional (albeit defective) interaction domain. It will be clear to the person of ordinary skill that whether an interaction domain of the present invention, variant, derivative, or fragment thereof retains its function in binding to its partner can be readily determined by using the teachings and assays of the present invention and the general teachings of the art.
  • the interaction domains of the present invention can be modified, for example by in vitro mutagenesis, to dissect the structure-function relationship thereof and permit a better design and identification of modulating compounds.
  • some derivative or analogs having lost their biological function of interacting with their respective interaction partner may still find utility, for example for raising antibodies.
  • Such analogs or derivatives could be used for example to raise antibodies to the interaction domains of the present invention.
  • These antibodies could be used for detection or purification purposes.
  • these antibodies could also act as competitive or non-competitive inhibitor and be found to be modulators of an interaction identified in accordance with the present invention.
  • a host cell or indicator cell has been "transfected" by exogenous or heterologous DNA (e.g. a DNA construct) when such DNA has been introduced inside the cell.
  • the transfecting DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell.
  • the transfecting DNA may be maintained on a episomal element such asa plasmid.
  • a stably transfected cell is one in which the transfecting DNA has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication.
  • the term therapeutic agent should be taken in a broad sense so as to also include a combination of at least two such therapeutic agents.
  • the DNA segments or proteins according to the present invention can be introduced into individuals in a number of ways. For example, erythropoietc cells can be isolated from the afflicted individual, transformed with a CNA construct according to the invention and reintroduced to the afflicted individual in a number of ways, including intravenous injection.
  • the DNA construct can be administered directly to the afflicted individual, for example, by injection in the bone marrow.
  • the therapeutic agent can also be delivered through a vehicle such as a liposome, which can be designed to be targeted to a specific cell type, and engineered to be administered through different routes.
  • the prescribing medical professional will ultimately determine the appropriate form and dosage for a given patient, and this can be expected to vary according to the chosen therapeutic regimen (e.g. DNA construct, protein, molecule), the response and condition of the patient as well as the severity of the disease.
  • the chosen therapeutic regimen e.g. DNA construct, protein, molecule
  • composition within the scope of the present invention should contain the active agent (e.g. protein, nucleic acid, or molecule) in an amount effective to achieve the desired therapeutic effect while avoiding adverse side effects.
  • the nucleic acids in accordance with the present invention can be administered to mammals (e.g. humans) in doses ranging from 0.005 to 1 mg per kg of body weight per day of the mammal which is treated.
  • Pharmaceutically acceptable preparations and salts of the active agent are within the scope of the present invention and are well known in the art (Remington's Pharmaceutical Science, 16th Ed., Mack Ed.).
  • the amount administered should be chosen so as to avoid adverse side effects.
  • the dosage will be adapted by the clinician in accordance with conventional factors such as the extent of the disease and different parameters from the patient. Typically, 0.001 to 50 mg/kg/day will be administered to the mammal.
  • protein-protein interactions can have many measurable effects, such as: i) changes in the kinetic properties ofone or both proteins (21, 22); ii) formation of new binding or functional sites (14, 25); and iii) the inactivation of function(s) (27, 30).
  • a given protein could expose different functional domains or sequences in the presence as opposed to the absence of any interacting proteins.
  • protein A can expose other sequences not previously exposed for interactions with other proteins (14, 21, 22, 25, 27, 30).
  • dimerization a subset of protein-protein interactions is dimerization.
  • homo- or heterodimers include; growth factor receptors (9); membrane transport proteins (2, 7, 18); tumor suppressor proteins (16); and proteins that mediate apoptosis (23).
  • dynamic dimerization is a common theme in the regulation of signal transduction.
  • Some of the functional consequences of dimerization include, increased proximity for activation of single transmembrane cell surface receptors (e.g., EGF receptor (9)) and differential regulation by heterodimerization [e.g., BCL2 family of proteins (23)].
  • the protein concentration in living cells is very high and is in the range of 10-30 mg/ml. At this high protein concentration, most if not all proteins should interact precisely and specifically with other cellular proteins. Someof the interacting proteins act as inhibitors of function, while others may be activators [e.g. The BCL2-BAX family of proteins, (23)]. Moreover, the cycling of a given protein between activator and inhibitor association will require the association-dissociation process to occur rapidly. For example, when protein X is associated with an inhibitor protein I, the domains (small sequences) that are required for the association of protein X with an activator protein A may not be easily accessible in the X-I complex.
  • the method of the present invention is capable of identifying all functional domains or high-affinity interacting domains of protein X and its associated proteins. Once the associated proteins are identified, their biological functions as it relates to the target protein X can be tested.
  • the high-affinity binding sequences (between protein X and Protein I or A) can be easily identified and can be used as a target site in a high throughput drug screening assays (see below) or other assays.
  • This invention includes the concept [described in Figures A-D] that protein-protein interactions are made-up of discontinuous high-affinity binding and high-repulsive forces scattered throughout the 3D sequence of proteins and that these sequences can be isolated using one of many possible approaches indicated herein (e.g. the overlapping peptide approach). Although, in this application, the overlapping peptide approach is exemplified, other approaches can be envisioned that give similar results. It should be stressed that the approach described herein is immune to conformational changes resulting from interacting proteins that could affect other commonly used methods to identify protein-protein interactions (e.g., two-hybrid system, affinity blotting, and crosslinking).
  • Protein A is fused with another protein sequence (the DNA-bound "bait” protein) and the other interacting protein is fused to the activation-domain containing "prey” protein.
  • the fusion of interacting proteins to protein A could expose regions other than those found in the native conformation which will affect their interactions.
  • the two-hybrid system has several disadvantages, some of which are listed below,
  • the present approach and methodology used to identify discontinuous strings of sequences between two or more interactive proteins is a scanning overlapping peptide approach.
  • a large number of short overlapping peptides which cover the entire amino acid sequence of the a given protein "the bait" are synthesized in parallelon an inert solid support [See Figure 2].
  • the rationale for synthesizing a large number of overlapping peptides as opposed to a discontinuous peptide library is based on the fact that one does not know a priori what exact sequence of a given protein will contain the high affinity binding sites and the repulsive sequences. Therefore, a discontinuous peptide approach will often lead to the presence of both high affinity binding sequences and repulsive sequences in the same peptide.
  • Such peptides will nd bind to potential interacting proteins with high affinity.
  • the use of overlapping peptides also provides internal controls for unspecific binding.
  • the high affinity bindingsequences will give a peak of signal when peptides within the high affinity domain will have the high affinity amino acid sequences but will lack amino acids which provide the repulsive forces [See figure 6 in Example I].
  • overlapping peptides can be derived from a chosen domain of a protein. Also, it would be envisageable to probe an overlapping peptide side set of a first protein wth an overlapping peptide set of a second protein.
  • P-glycoprotein is a membrane protein (8) that confers resistance to anticancer drugs and therefore is responsible for the failure of chemotherapy.
  • P-glycoprotein has been shown to function by preventing the accumulation of chemotherapeutic drugs in tumor cells; the exact mechanism of haw this protein functions and what are the associated proteins that modulate its functionare not known.
  • the peptides and total cell lysate were incubated in the presence of a carrier substrate (1-3% Bovine Serum Albumin, or 1-3% gelatin, 1-3% Skim milk, etc..) for 18 hours at 4°C. Following this incubation period, the covalently fixed peptides were washed extensively with isotonic buffer. Any proteins from the radiolabeled total cell lysate which maintained their association with the overlapping hexapeptides following the washing step are eluted in SDS-contain sample buffer and analyzed on SDS polyacrylamide gel electrophoresis (SDS-PAGE) (12). The presence of radiolabeled proteins on SDS-PAGE following gel drying and signal enhancement, provides the following information:
  • the associated proteins which bound to the high affinity binding sequences can be isolated in large quantities for the purpose of determining their identity by N-terminal amino acid sequencing by Edman degradation (28) or the like. Briefly, the sequences of the overlapping peptides that bounda given protein are resynthesized on a solid support and kept fixed thereto. Total cell lysate from [ 35 S]methionine metabolically radiolabeled cells is added to the solid support containing the fixed high affinity sequence peptides and incubated as described above. Following washing steps to remove unbound material, the associated protein is isolated in large amounts following an elution step with SDS-containing buffers (see below). The purified associated protein is now ready for amino acid sequencing. Of course, should further purification steps be required, they are well known to the skilled artisan. The purified protein is ran on SDS-PAGE and the resolved protein is transferred to PVDF membrane as previously described (1). Other methods for amino acid sequence determination can also be easily applied (26).
  • the same concept as described above can be applied if one is only interested in identifying the high affinity binding sequences between two proteins.
  • a non-limiting example of such two proteins are the regions of interactions between p53 and MDM (3, 24).
  • the purpose of this exercise is to identify the high affinity binding sequences between proteins A (p53) and protein B (MDM) in order to use these sequences as target sites for the identification of compounds that modulate this interaction and more particularly for the development of drugs.
  • a given drug when a given drug is bound to one of these high affinity binding sites on protein A, it will prevent the formation of the active complex (protein A+B) and therefore inhibit the functions of the complex.
  • an enriched and radiolabeled full-length protein B "the prey” (the radiolabeled protein B is easily obtained from in vitro transcription-translation reactions; (31)) is added to each well of the 96-well plate that contain the covalently fixed overlapping peptides.
  • the peptides encoding protein A are incubated with radiolabeled protein B to allow for binding tooccur. Following an incubation period (5 to 24 hours), unbound radiolabeled protein B will be removed by extensive washing in isotonic buffer. Any overlapping peptides which bound to radiolabeled protein B will be eluted in the presence of denaturing agents.
  • the eluant from each of the 96-well plates are analyzed for the presence of radiolabeled protein B by running the samples on SDS PAGE (12). High-affinity binding peptides will be identified as those that retain the radiolabeled Protein B.
  • metabolically radiolabeled proteins as “the prey” to interact with the overlapping peptides encoding "the bait”, increases the sensitivity of this technique and allows the identification of interacting proteins with binding affinities of 10 10 - 10 12 M for a standard 50 kDa protein which encodes one to ten radiolabeled methionine residues (20).
  • the approach, described herein, to identify high-affinity binding sequences or target sites for drug development can also be used in high throughput assays to screen for small molecules from combinatorial libraries. For example, to select drugs that specifically inhibit the binding of protein A to B [see Figure 4].
  • One or more target sites are synthesized in each of the 96-well plates as described earlier.
  • Figure 4 the same high affinity binding sequence is synthesized in all of the wells.
  • a radiolabeled protein B from an in vitro transcription-translation mix for example, is added and allowed to incubate as indicated above.
  • bound protein B is eluted with SDS-sample buffer.
  • Wells containing radiolabeled protein B indicates that the drug had no effect on the binding between the high affinity binding sequence and protein B.
  • that drug has inhibited the interactions between the high affinity binding sequence from A and protein B.
  • the latter drug is a good LEAD compound.
  • the present invention also provides quantitative assays to measure the protein-protein interaction and the modulation thereof by compounds.
  • P-glycoprotein binding to tubulin is mediated by sequences in the linker domain
  • MDR multidrug resistant tumor cells
  • P-gp P-glycoprotein
  • MRP1 multidrug resistance-associated protein
  • P-gp1 Although, the structure of P-gp1 remains a matter speculation (60), cumulative topological evidence suggest a tandemly duplicated structure of six transmembrane domains and a large cytoplasmic domain encoding an ATP binding sequence (45, 51). The two halves of P-gp1 are linked by a stretch of 90 residues rich in polar or charged amino acids, termed the Linker domain.
  • the P-gp gene family is made up of three structurally similar isoforms in rodents (classes I, II, and III) and two isoforms in humans (classes I and III) (14). Gene transferstudies suggest functional differences among these structurally similar isoforms. For example, only the P-gp isoforms of classesl and II confer the MDR phenotype (18, 73), while the class III isoforms do not (7, 65). The class III isoforms mediate the transfer of phosphatidylcholine from the inner to the outer leaflet of the plasma membrane (i.e., "flipase") (61, 67).
  • P-gp distribution is restricted mainly to tissues with secretory functions (55, 76). Its polarized localization to apical surfaces facing a lumen in the adrenal gland, liver, kidney intestine suggests a normal transport or detoxification mechanism. Moreover, hematopoietic stem cells and specific lymphocyte subclasses also express high levels of P-gp (37).
  • the normal function or substrate(s) of the classes I and II remain undefined; however, the disruption of the class I or/and II genes from the mouse genome results in the accumulation of cytostatic drugs or lipophilic compounds in most normal tissues but more strikingly in the brain (66, 67). Based on these results it is speculated that the normal function of P-gp (the class I and II or the MDR causing P-gp) is detoxification similar to that seen in MDR cells, especially at the blood brain barrier (44).
  • P-gp was shown to be a substrate for protein kinases C and A (2 9). Moreover, it has been demonstrated that agents, which modulate protein kinase C activity, modulate P-gp phosphorylation and its MDR-mediate phenotype (4, 8).
  • PMA phorbol ester (a protein kinase C activator) was shown to increase the MDR phenotype and drug efflux in MCF7 breast cancer cells.
  • sodium butyrate treatment of SW620 human colonic carcinoma cells was shown to result in a large increase in P-gp expression without a concomitant increase in drug-resistance or -efflux.
  • the latter assay is based on the novel understanding of protein interactions provided by the present invention.
  • the results show hereinbelow that three sequences in the linker domain bind to proteins with apparent molecular masses of ⁇ 80 kDa, 57 kDa and 30 kDa.
  • Purification and partial N-terminal amino acid sequencing of the 57 kDa protein showed that it encodes the N-terminal amino acids of ⁇ and ⁇ -tubulins.
  • this domain is bound specifically to proteins; ii) the specifically binding proteins can be formerly identified; and iii) the sequence responsible for the specific binding of these proteins formerly identified (together with the interacting domain of this binding protein, if derived).
  • [ 35 S] methionine (1000 Ci/mmol; Amersham Life Sciences, Inc.) and [ 125 I] goat anti-mouse antibody were purchased from Amersham Biochemical Inc. Protein-A Sepharose-4B was purchased from Bio-Rad Life Science. All other chemical used were of the highest commercial grade available.
  • Prederivatized plastic rods, active ester and polypropylene trays were purchased from Cambridge Research Biochemicals (Valley Stream, NY). Peptides were synthesized on solid polypropylene rods as previously described (27, 28). Briefly, the F-moc protecting group on the prederivatized polypropylene rods as solid support (arranged in a 96-well formate) was removed by incubation with 20% (v/v) piperidine in dimethylformamide (DMF) for 30 minutes with shacking. Following the deprotection of the ⁇ -alanine spacer on the polypropylene rods, Fmoc protected amino acids were dissolved in HOBt/DMF and added to the appropriate wells containing deprotected rods.
  • DMF dimethylformamide
  • the F-moc N-terminal protecting group was removed with 20% piperidine/DMF and the free amino group acetylated for 90 minutes in an acetylation cocktail containing acetic anhydride: diisopropylethylamine (DIEA): DMF (50:1:50 v/v/v).
  • DIEA diisopropylethylamine
  • the side chain protecting groups of the N-terminal acetylated hexapeptides onto the polypropylene rods were removed by incubation in a cleavage mixture containing trifluoroacetic acid phenol: ethandithiol (95:2.5:2.5 v/v/v) for 4 hours at room temperature.
  • the rods were washed with dichloromethane (DCM) and neutralized in 5% (v/v) DIEA/DCM.
  • DCM dichloromethane
  • the deprotected peptide-coupled rods were washed in DCM, methanol and vacuum dried for 18 hours.
  • CEM Drug sensitive
  • CEM/VLB 1.0 Drug sensitive cells
  • ⁇ -MEM media supplemented with 10% fetal calf serum (Hyclon Inc.) as previously described (6). All cells were examined for Mycoplasma contamination every three months using the Mycoplasma PCR kit from Stratagene Inc. San Diego, CA.
  • CEM or CEMNLB 1.0 cells at 70-80% confluency were metabolically labeled witt 35 [ S] methionine (100 ⁇ Ci/ml) for 6 hours at 37C in methionine-free ⁇ -MEM media.
  • hypotonic buffer 10 mM KCI, 1.5 mM MgCl 2 , 10 mM Tris-HCl, pH 7.4
  • protease inhibitors 2 mM PMSF, 3 ⁇ g/ml Leupeptin, 4 ⁇ g/ml pepstatin A and 1 ⁇ g/ml aprotinin
  • Cells were lysed by homogenization in a hypotonic buffer and the cell lysate was sequentially centrifuged at 6000 xg for 10 minutes.
  • the supernatant was removed and made 0.5 M NaCl final concentration from a stock solution of 4 M NaCl.
  • the cell lysate was incubated on ice for 30 minutes. The sample was mixed and brought back to 0.1 M NaCl final concentration. The cell lysate was centrifuged for 10 minutes at 15,000 Xg at 4°C. The latter supematant was removed and recentrifuged at 100,000 Xg for 60 minutes in a Beckman ultracentrifuge using SW55 rotor. The amount of protein in the above samples was determined by the method of Lowry (52).
  • [ 35 S] methionine labeled proteins from total cell lysate were mixed with equal volume of 3-6%BSA in phosphate buffered saline (PBS) and incubated with overlapping hexapeptides covalently fixed to polypropylene rods.
  • the peptides and total cell lysate were incubated overnight at 4°C.
  • the rods were then removed and washed four times in PBS.
  • the bourd proteins were eluted by incubating the peptide-fixed rods in 1X SDS sample butter for 60 minutes at room temperature with shacking.
  • the peptides-fixed rods were regenerated by incubation in PBS, containing 2% SDS and 1 mM ⁇ -mercaptoethanol at 65°C in a sonicator for 30 minutes. Following the latter incubation, the rods were washed for five minutes in 65°C ionized water and two minutes in 65°C methanol. The peptides-fixed rods are now ready for the next round of screening.
  • [ 35 S] methionine labeled proteins from total cell lysate were mixed with equal volume of 3%BSA in phosphate buffered saline containing KCI (300 mM to 1200 mM), SDS (0.12% to 2%), or CHAPS (20 mM to 160 mM) and incubated with covalently fixed peptides as described above.
  • Protein fractions (100-150 ⁇ l) were resolved on SDS-PAGE using the Laemmli gel system (47). Br/iefly, proteins were dissolved in 1X solubilization sample buffer I (62.5 mM Tris-HCl, pH 6.8, containing 2% (w/v) SDS, 10% (w/v) glycerol and 5% ⁇ -mercaptoethanol) and samples were electrophoresed at constant current. Gel slabs containing the resolved proteins were fixed in 50% methanol and 10% acetic acid. Polyacrylamide gels containirg [ 35 S] methionine proteins were exposed to Kodak x-ray film following a thirty-minute incubation in an AmplifyTM solution (Amersham Inc.).
  • proteins were transferred to nitrocellulose membrane in Tris-glycine buffer in the presence of 20% methanol for Western blot analysis according to the procedure of Towbin et al., (71).
  • Nitrocellulose membrane was incubated in 5% skim milk/PBS prior to the addition of anti- ⁇ or anti- ⁇ tubulin monoclonal antibodies (0.5 ⁇ g/ml in 3% BSA; Amersham, Inc.). Following several washes with PBS, the nitrocellulose membrane was incubated with goat anti-mouse peroxidase conjugated antibody and immunoreactive proteins were visualized by chemiluminescence using ECL method (Amersham Inc.).
  • the 57 kDa associated protein was purified using a block of polypropylene rods with two high affinity binding peptides. Briefly, the peptide-fixed rods were incubated with total cell lysate as indicated above, however, in this case the carrier substance was gelatin (1%). The bound proteins were eluded in 100 mM phosphate buffer, pH 7.4 containing 2% SDS and 0.1% ⁇ -mercaptoethanol. The eluted proteins were precipitated by mixing with 9 volumes of ice cold ethanol and incubated at -20 °C.
  • P-gp is a tandemly duplicated molecule made up of two halves with each encoding for six transmembrane domains and an ATP binding domain. The two halves of P-gp are linked by a linker domain. Of the 90 amino acids that make up the linker domain, 32 amino acid are either positively or negatively charged at physiological pH. While P-gp phosphorylation sites appear to have relevance to P-gp function, the function of the linker domain of P-gp remains unknown. To identify and dissect the role of this domain in MDR, the overlapping peptides method of the present invention was used. A novel approach was developed to isolate interacting proteins using overlapping synthetic hexapeptides.
  • Figure 5 shows the amino acid sequences of the linker domain of P-gp 1 and P-gp 3.
  • the two linker domains of P-gp1 and P-gp3 share 41 % amino acid sequence identity or 66% sequence homology.
  • Overlapping hexapeptides were synthesized in parallel on derivatized polypropylene rods as previously described (25, 27). 92 and 90 hexapeptides were synthesized to cover the entire linker sequence of P-gp1 and P-gp3, respectively. The hexapeptides remain covalently attached to the polypropylene rods.
  • the peptide-fixed rods were incubated with total cell lysate from [ 35 S] methionine metabolically labeled CEM or CEM/VLB 1.0 cells. After washing off non-specifically binding lysate proteins, the specifically bound proteins were eluded with SDS containing buffers and resolved on SDS PAGE.
  • Figure 6 shows the proteins specifically bound to the 92 overlapping hexapeptides from P-gp1 linker sequence.
  • Three regions in P-gp1 linker domain ( 617 EKGIYFKLVTM 627 , 657 SRSSLIRKRSTRRSVRGSQA and 693 PVSFWRIMKLNLT 705 ) bound a 57 kDa protein.
  • the hexapeptides numbers 46-60, 81-89 and 5-9 (see figure 5) bound with decreasing affinities to the 57 kDa protein ( Figure 6).
  • peptides 46-60 showed binding to two other proteins with apparent molecular masses of 80 kDa and 30 kDa, however much weaker than that of 57 kDa.
  • hexapeptides 3-10 bound to ⁇ 210 kDa protein that was not detected previously in the absence of CHAPS.
  • hexapeptides 16-20 which did not bind any proteins in the absence of CHAPS, bound to the same high molecular weight protein (Figure 7).
  • Peptides 40-60 bound more strongly to several low molecule weight proteins ( ⁇ 45-25kDa) in the presence of CHAPS.
  • the hexapeptides 80-89 bound to two other proteins in addition to the 57 kDa protein.
  • the solubilization of membrane proteins in 10 mM CHAPS show binding to other proteins not seen in the absence or 10 mM CHAPS.
  • 10 mM CHAPS allows integral membrane proteins to interact with the various hexapeptides of P-gp 1 linker domain.
  • CHAPS exposes new domains that in turn allows for binding to hexapeptides of P-gp1 linker domain.
  • some of the lower molecular weight proteins that bound to hexapeptides 40-60 and 80-89 may be degradation products of the 57 kDa protein (figure 8).
  • the P-gp gene family in man is encoded by two isoforms, P-gp 1 and P-gp 3 (or mdr 1 and mdr 3; (14)). However, as indicated earlier, only P-gp 1 confers an MDR phenotype. Moreover, although P-gp 1 and 3 share about 80% amino acid sequence homology (73); the linker domain is the most variable domain among the two isoforms with 66% amino acid sequence homology. To determine if the P-gp 3 linker domain binds to the same or different proteins, overlapping hexapeptides encoding P-gp 3 linker domain were synthesized on polypropylene rods and their binding to soluble proteins was examined as indicated above.
  • Figure 9 shows the profile of binding proteins to the hexapeptides of P-gp 3.
  • a similar molecularweight protein (57 kDa) also bound to the hexapeptides from P-gp 3.
  • the binding to some hexapeptides was different from that seen with P-gp 1 (figure 6 versus figure 9).
  • three larger stretches of amino acids 618 LMKKEGVYFKLVNM 631 , 648 KAATRMAPNGWKSRLFRHSTQKNLKNS 674 and 695 PVSFLKVLKLNKT 677 ) bound to the 57 kDa protein.
  • the first and third regions of P-gp 3 linker domain share considerable sequence identity with the first and third regions of P-gp 1 linker domain (figure 10). Hence, it is not surprising that the same hexapeptides bound to the same protein.
  • the second region of P-gp 1 and P-gp 3 linker domains are different (figure 10). Consequently, although both the P-gp1 and P-gp3 sequences bound to a 57 kDa, the region of interaction between P-gp 3 and the 57 kDa protein is larger than that of P-gp 1 (figure 6 and figure 9).
  • a comparison of the amino acid sequences from P-gp 1 and P-gp 3 binding hexapeptides is shown in Figure 10.
  • Figure 12 shows the effects of no blocking carrier, 1% gelatin and 0.3% or 3% BSA on the binding of the hexapeptides to the 57 kDa protein. These results of this experiment were surprising in that no carrier protein was required to reduce the unspecific binding (figure 12). The latter established binding conditions were used to isolate large amounts of 57 kDa protein that bound to several copies of hexapeptides 658 RSSLIR 663 and 669 SVRGSQ 674 .
  • Figure 13 shows purified 57 kDa protein on SDS-PAGE stained with Coomassie blue.
  • the latter purified protein was transferred to PVDF membrane and stained with Ponceau S to localize the position of the 57 kDa protein.
  • the Ponceau S stained band that migrated with the expected molecular mass was cut out and used for direct N-terminal sequencing (22).
  • the first seven rounds of Edman degradation showed two sequences of MREVISI and MREIVHI. These two sequences differed only by three amino acids (VIS instead of IVH). Comparison of the two sequence with known protein sequences using FastA protein search engine, showed the latter sequences to encode the first seven N-terminal amino acids of ⁇ - and ⁇ -tubulins.
  • tubulins as the 57 kDa protein was consistent with the apparent molecular mass and the potential degradation products that were observed following long incubation periods.
  • Western blot analysis was preformed on hexapeptide-bound 57 kDa protein and total cell lysate resolved on SDS PAGE and transferred to nitrocellulose membrane. The nitrocellulose membrane was then probed with anti ⁇ -tubulin and anti- ⁇ -tubulin monoclonal antibodies, respectively.
  • Figure 14 shows the results of the Western blot analysis. Consistent with the sequencing results, both tubulin subunits ( ⁇ and ⁇ ) were recognized in the lanes containing the hexapeptide bound proteins. Thus, establishing the identity of the 57 kDa protein as ⁇ and ⁇ -tubulin.
  • the overlapping peptide-based method of the present invention provides the proof of principle to the hypothesis which states that the region between two interacting proteins consists of high affinity binding sequences and repulsive sequences as well as the fact thatsuch a method can be used efficiently and successfully to identify and characterize domains and sequences of interacting proteins.
  • the balance of high affinty and repulsive forces determine whether two proteins will form stable complex.
  • the use of short overlapping peptides allows the identification of such high affinity binding sequences between bait and prey proteins.
  • the rationale for using short and overlapping peptides to isolate high affinity binding sequences is essential to the success and efficiency of the proof of the principle described herein.
  • larger peptides could contain both high affinity and repulsive binding sequences in one peptide sequence such that the net force of interaction is negative.
  • the use of overlapping peptides that differ in one amino acid from the previous or next peptide reduces the possibility of unspecific binding.
  • overlapping peptides often demonstrate a peak in the binding affinity of various peptides (see figures 7 and 4).
  • the skilled artisan will understand that longer overlapping peptides could also be used.
  • such larger peptides increase the risk of missing the identification of interacting proteins due to a change in the balance between high-affinity and repuisive amino acids.
  • the binding of 57 kDa protein to three different regions in P-gp1 and P-gp3 linker domains is consistent with the herein proposed hypothesis to explain protein interactions (see principle of protein-protein interactions).
  • the high affinity binding domains vary in sizes from 10 -26 amino acids in length.
  • two of the three high affinity binding domains shared considerable sequence identity.
  • the third high affinity binding region of the linker domains ( 658 SRSSLIRKRSTRRSVRGSQA 677 versus 648 KAATRMAPNGWKSRLFRHSTQKNLKNS 674 ) shared no homology in their primary amino acid sequence.
  • 57 kDa protein binds to the polypropylene rods or their derivatized moieties since all other rods which are similarly derivatized did not bind the 57 kDa protein.
  • other proteins with apparent molecular masses of ⁇ 80 kDa and 30 kDa also bound to some of the hexapeptides in the linker domains.
  • tubulin has been shown to interact with several membrane proteins (38, 31, 56, 57).
  • P-gp1 or P-gp3 interactions with tubutin and possibly microtubules maybe an example of the membrane-skeleton fence model (43).
  • cytoskeleton 64.
  • increase in the stability and expression of P-gp in rate liver tumors in vivo are associated with similar increases in the stability of several cytoskeleton proteins, including ⁇ -tubulin, ⁇ -actin, and cytokeratins 8/18 (48). Work is in progress to determine the functional significance of P-gp interactions with tubulin in vivo.
  • the overlapping peptides spanning method is not limited to Pgp-interacting proteins
  • Annexin I a soluble and membrane associated protein, as opposed to P-glycoprotein, a strictly transmembrane protein.
  • Annexin is thus structurally and functionally different from P-glycoprotein.
  • Annexin I is a member of a large family of intracellular soluble and membrane associated proteins that bind phospholipids in a reversible and calcium-dependent manner.
  • Various members of the Annexh family have been implicated in a number of different intracellular processes including vesicular trafficking, membrane fusion exocytosis, signal transduction, and ion channel formation and drug resistance.
  • the method of the present invention was setout to identify its interacting proteins and the precise amino acid sequences that mediate Annexin I interactions thereto.
  • overlapping peptides corresponding to the entire amino acid sequence of Annexin I were synthesized on a solid support as described above.
  • overlapping heptapeptides, as opposed to hexapeptides were used.
  • the peptides were then incubated with total cellular proteins isolated from MCF7 breast tumor cells that were metabolically labeled with [35S] methionine. Following several washes, the bound proteins were eluted and resolved on SDS-PAGE as outlined above.
  • the present invention is shown to enable the simple and efficient identification of high-affinity protein interaction as well as enabling the simultaneous identification of the precise amino acid sequence of at least one of the interacting partners.
EP06000197A 1999-05-14 2000-05-12 Verfahren zur Identifizierung von Modulatoren wechselwirkender Proteine Ceased EP1684077A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13425999P 1999-05-14 1999-05-14
EP00929188A EP1179186B1 (de) 1999-05-14 2000-05-12 Methoden zur identifizierung von modulatoren wechselwirkender proteine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP00929188A Division EP1179186B1 (de) 1999-05-14 2000-05-12 Methoden zur identifizierung von modulatoren wechselwirkender proteine

Publications (1)

Publication Number Publication Date
EP1684077A1 true EP1684077A1 (de) 2006-07-26

Family

ID=36589557

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06000197A Ceased EP1684077A1 (de) 1999-05-14 2000-05-12 Verfahren zur Identifizierung von Modulatoren wechselwirkender Proteine

Country Status (1)

Country Link
EP (1) EP1684077A1 (de)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984003564A1 (en) * 1983-03-08 1984-09-13 Commw Serum Lab Commission Method of determining antigenically active amino acid sequences
EP0818467A2 (de) * 1996-07-12 1998-01-14 Nec Corporation Ausgerichtete Peptid-Anordnung und ein rationelles und schnelles Verfahren zum Nachweis einer Bindung oder einer Wechselwirkungsstelle eines Proteins mittels deren
WO1998015833A1 (en) * 1996-10-08 1998-04-16 Universiteit Utrecht Methods and means for selecting peptides and proteins having specific affinity for a target

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984003564A1 (en) * 1983-03-08 1984-09-13 Commw Serum Lab Commission Method of determining antigenically active amino acid sequences
EP0818467A2 (de) * 1996-07-12 1998-01-14 Nec Corporation Ausgerichtete Peptid-Anordnung und ein rationelles und schnelles Verfahren zum Nachweis einer Bindung oder einer Wechselwirkungsstelle eines Proteins mittels deren
WO1998015833A1 (en) * 1996-10-08 1998-04-16 Universiteit Utrecht Methods and means for selecting peptides and proteins having specific affinity for a target

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CIANFRIGLIA M. ET AL.: "P-glycoprotein epitope mapping: II. The murine monoclonal antibody MM6.15 to human multidrug-resistant cells binds with three distinct loops in the MDR1-P-glycoprotein extracellular domain", INTERN. J. CANCER, vol. 61, 1995, pages 142 - 147, XP000957487 *
ELLGAARD L ET AL: "Nested sets of protein fragments and their use in epitope mapping: characterization of the epitope for the S4D5 monoclonal antibody binding to receptor associated protein", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 180, no. 1, 13 March 1995 (1995-03-13), pages 53 - 61, XP004021070, ISSN: 0022-1759 *
GEORGES E. ET AL.: "Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies", PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 152 - 156, XP002150436 *
GEORGES E. ET AL.: "Topology of P-glycoprotein as determined by epitope mapping of MRK-16 monoclonal antibody", J. BIOL. CHEM., vol. 268, no. 3, 1993, pages 1792 - 1798, XP002150421 *
KITAY MARY KATE ET AL: "Protein-protein interactions between Epstein-Barr virus nuclear antigen-iP and cellular gene products: Binding of 70 kilodalton heat shock proteins", VIROLOGY, vol. 220, no. 1, 1996, pages 91 - 99, XP002384214, ISSN: 0042-6822 *
RIVERO-LEZCANO O M ET AL: "Specificity of protein interactions with highly related SRC homology (SH) domains of FGR and FYN protein-tyrosine kinases.", FEBS LETTERS. 31 JAN 1994, vol. 338, no. 2, 31 January 1994 (1994-01-31), pages 183 - 186, XP002384213, ISSN: 0014-5793 *

Similar Documents

Publication Publication Date Title
US20080009068A1 (en) Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction
Nolan et al. The bcl-3 proto-oncogene encodes a nuclear IκB-like molecule that preferentially interacts with NF-κB p50 and p52 in a phosphorylation-dependent manner
US8349798B2 (en) Caveolin peptides and their use as therapeutics
ES2625316T3 (es) Neuquinasa, una proteína corriente abajo de neuregulina
JP2002504818A (ja) リガンドファミリーのｎｔｎ−２メンバー
JPH10509312A (ja) ｐ２１▲上ＷＡＦ１▼−ＰＣＮＡ相互作用部位の同定とその治療における応用
JP2002544522A5 (de)
EP0692488A2 (de) Interleukin-4 Signalwandler und Bindungstests
EP0900273A2 (de) Familie von organischen anionentransportproteine , deren nukleinesäuren, zellen die sie enthalten und verfahren zu deren anwendung
US20070117138A1 (en) Splice variant cannabinoid receptor (cb1b)
UA110119C2 (xx) Пептиди tomm34 та вакцини, що їх містять
US7147855B2 (en) GIPs, a family of polypeptides with transcription factor activity that interact with goodpasture antigen binding protein
EP1684077A1 (de) Verfahren zur Identifizierung von Modulatoren wechselwirkender Proteine
US6261778B1 (en) Isolated nucleic acid molecules which encode SCP proteins, and uses thereof
KR20040010644A (ko) Ｅｐｆ 수용체 에세이, 화합물 및 치료학적 조성물
JP2003528599A (ja) Ｇタンパク質共役レセプター
US7211402B2 (en) Transcription factor coactivator protein, p/CIP
US7115381B1 (en) Methods for treating cardiovascular disorders
JP3739445B2 (ja) Ｅｃｄｎ蛋白質およびそれをコードするｄｎａ
KR20120109824A (ko) Ｐａｕｆ 및 그의 결합 파트너를 상호작용을 이용한 암 치료제의 스크리닝 방법
WO1999058566A1 (en) INHIBITION OF p53 FUNCTION BY A p53-DERIVED SUBSTANCE
JP2005527190A (ja) 核タンパク質「ｓｈｏｃａ」−ｗｎｔシグナル伝達経路の成分
JP2008510125A (ja) 大腸癌関連遺伝子Ｃ２０ｏｒｆ２０のｐ１２０との相互作用
AU2004222677A1 (en) Regulation of cell surface proteins
EP2167959A1 (de) Verfahren zum screening antiangiogener verbindungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1179186

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RTI1 Title (correction)

Free format text: PROTEIN-PROTEIN INTERACTIONS AND METHODS FOR IDENTIFYING THEM

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GEORGES, ELIAS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GEORGES, ELIAS

17P Request for examination filed

Effective date: 20070116

17Q First examination report despatched

Effective date: 20070226

AKX Designation fees paid

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20100702